124 related articles for article (PubMed ID: 30779266)
21. A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
Filion KB; Azoulay L; Platt RW; Dahl M; Dormuth CR; Clemens KK; Hu N; Paterson JM; Targownik L; Turin TC; Udell JA; Ernst P;
N Engl J Med; 2016 Mar; 374(12):1145-54. PubMed ID: 27007958
[TBL] [Abstract][Full Text] [Related]
22. Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study.
Kim YG; Yoon D; Park S; Han SJ; Kim DJ; Lee KW; Park RW; Kim HJ
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28899989
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position.
Giorda CB; Nada E; Tartaglino B; Marafetti L; Gnavi R
Diabetes Obes Metab; 2014 Nov; 16(11):1041-7. PubMed ID: 24702687
[TBL] [Abstract][Full Text] [Related]
24. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
Jermendy G
Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
[TBL] [Abstract][Full Text] [Related]
25. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
Bowker SL; Majumdar SR; Veugelers P; Johnson JA
Diabetes Care; 2006 Feb; 29(2):254-8. PubMed ID: 16443869
[TBL] [Abstract][Full Text] [Related]
26. The safety of incretin based drug treatments for type 2 diabetes.
Bolen SD; Maruthur NM
BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
[No Abstract] [Full Text] [Related]
27. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus.
Qiu H; Rhoads GG; Berlin JA; Marcella SW; Demissie K
Diabetes Obes Metab; 2013 Apr; 15(4):349-57. PubMed ID: 23137378
[TBL] [Abstract][Full Text] [Related]
28. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
29. Incretins, Diabetes, Pancreatitis and Pancreatic Cancer: What the GI specialist needs to know.
Forsmark CE
Pancreatology; 2016; 16(1):10-3. PubMed ID: 26795258
[TBL] [Abstract][Full Text] [Related]
30. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
Calip GS; Yu O; Elmore JG; Boudreau DM
Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250
[TBL] [Abstract][Full Text] [Related]
31. Sitagliptin and pancreatic cancer risk in patients with type 2 diabetes.
Tseng CH
Eur J Clin Invest; 2016 Jan; 46(1):70-9. PubMed ID: 26584246
[TBL] [Abstract][Full Text] [Related]
32. Incretin-based drugs and the risk of congestive heart failure.
Yu OH; Filion KB; Azoulay L; Patenaude V; Majdan A; Suissa S
Diabetes Care; 2015 Feb; 38(2):277-84. PubMed ID: 25205143
[TBL] [Abstract][Full Text] [Related]
33. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
Chai S; Yu S; Yang Z; Wu S; Gao L; Wang H; Zhang Y; Zhan S; Ji L; Sun F
BMJ Open Diabetes Res Care; 2019; 7(1):e000728. PubMed ID: 31641525
[TBL] [Abstract][Full Text] [Related]
34. Incretin-based drugs and risk of acute pancreatitis: A nested-case control study within a healthcare database.
Soranna D; Bosetti C; Casula M; Tragni E; Catapano AL; Vecchia CL; Merlino L; Corrao G
Diabetes Res Clin Pract; 2015 May; 108(2):243-9. PubMed ID: 25748827
[TBL] [Abstract][Full Text] [Related]
35. The effects of dual-therapy intensification with insulin or dipeptidylpeptidase-4 inhibitor on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A retrospective cohort study.
Jil M; Rajnikant M; Richard D; Iskandar I
Diab Vasc Dis Res; 2017 Jul; 14(4):295-303. PubMed ID: 28330386
[TBL] [Abstract][Full Text] [Related]
36. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
[No Abstract] [Full Text] [Related]
37. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Montvida O; Green JB; Atherton J; Paul SK
Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
[TBL] [Abstract][Full Text] [Related]
38. Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
Giorda CB; Picariello R; Nada E; Tartaglino B; Marafetti L; Costa G; Gnavi R
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):111-5. PubMed ID: 24622714
[TBL] [Abstract][Full Text] [Related]
39. Incidence of and risk factors for severe hypoglycaemia in treated type 2 diabetes mellitus patients in the UK--a nested case-control analysis.
Bruderer SG; Bodmer M; Jick SS; Bader G; Schlienger RG; Meier CR
Diabetes Obes Metab; 2014 Sep; 16(9):801-11. PubMed ID: 24612200
[TBL] [Abstract][Full Text] [Related]
40. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
